TY - JOUR
T1 - ISHLT consensus document on lung transplantation in patients with connective tissue disease
T2 - Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements
AU - Crespo, Maria M.
AU - Claridge, Tamara
AU - Domsic, Robyn T.
AU - Hartwig, Matthew
AU - Kukreja, Jasleen
AU - Stratton, Kathleen
AU - Chan, Kevin M.
AU - Molina, Maria
AU - Ging, Patricia
AU - Cochrane, Adam
AU - Hoetzenecker, Konrad
AU - Ahmad, Usman
AU - Kapnadak, Siddhartha
AU - Timofte, Irina
AU - Verleden, Geert
AU - Lyu, Dennis
AU - Quddus, Sana
AU - Davis, Nicole
AU - Porteous, Mary
AU - Mallea, Jorge
AU - Perch, Michael
AU - Distler, Olivier
AU - Highland, Kristin
AU - Magnusson, Jesper
AU - Vos, Robin
AU - Glanville, Allan R.
N1 - Publisher Copyright:
© 2021 International Society for Heart and Lung Transplantation
PY - 2021/11
Y1 - 2021/11
N2 - Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.
AB - Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.
KW - biologic disease-modifying anti rheumatic drugs
KW - connective tissue diseases
KW - consensus statement
KW - esophageal disorders post-transplant medical and surgical management
KW - feedings
KW - lung transplantation
UR - http://www.scopus.com/inward/record.url?scp=85114781488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114781488&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2021.07.013
DO - 10.1016/j.healun.2021.07.013
M3 - Article
C2 - 34474940
AN - SCOPUS:85114781488
SN - 1053-2498
VL - 40
SP - 1279
EP - 1300
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 11
ER -